ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
| Year | Korea | Australia | The United kingdom | Japan |
|---|---|---|---|---|
| Keytruda® (pembrolizumab) | ||||
| 2015 | Melanoma (MES) | Melanoma (MAA) | ||
| 2017 | Non-small cell lung cancer 2nd line | Hodgkin lymphoma 2nd line (SC) |
• Non-small cell lung cancer 2nd line (CAA) • Melanoma (CAA) |
• Melanoma • Non-small cell lung cancer |
| 2018 | Melanoma |
• Urothelial carcinoma 2nd line (SC) • Non-small cell lung cancer (SC) |
• Urothelial carcinoma 2nd line (CAA) • Non-small cell lung cancer (CAA) • Hodgkin lymphoma 2nd line w/o stem cell transplant (MAA) |
• Hodgkin lymphoma • Urothelial carcinoma • Price discount 11.2% (dosage and administration change: comparable drug of Opdivo®) |
| 2020 | Price discount 41.0% (huge seller) | |||
| 2021 | Price discount 47.8% (market expansion: comparable drug of Tecentriq®) | |||
| 2022 |
• Non-small cell lung cancer • Hodgkin lymphoma 2nd line • Urothelial carcinoma 2nd line |
Hodgkin lymphoma after stem cell transplant or 2nd line w/o stem cell transplant (CAA) | ||
| Opdivo® (nivolumab) | ||||
| 2014 | Melanoma | |||
| 2015 | Non-small cell lung cancer | |||
| 2016 | Melanoma (rebate only) |
• Melanoma (rebate only) • Non-small cell lung cancer 2nd line (MAA) |
• Renal cell carcinoma • Hodgkin lymphoma |
|
| 2017 | Non-small cell lung cancer 2nd line | Non-small cell lung cancer 2nd line (SC) |
• Hodgkin lymphoma (PAS) • Non-small cell lung cancer (MAA) • Head and Neck Squamous Cell Carcinoma (MAA) |
• Head and neck squamous cell carcinoma 2nd line • Gastric adenocarcinoma • Price discount 50.0% (huge seller) |
| 2018 | Melanoma |
• Head and neck squamous cell carcinoma (SC) • Renal cell carcinoma (w Yervoy®, SC) |
Price discount 76.2% (dosage and administration change) | |
| 2019 | Renal cell carcinoma (w Yervoy®, MAA) | |||
| 2021 |
• Renal cell carcinoma (w Yervoy®) • Hodgkin lymphoma 2nd line • Head and neck squamous cell carcinoma 2nd line |
Price discount 78.8% (market expansion: comparable durg of Tecentriq®) | ||
| 2023 | Gastric adenocarcinoma, Gastroesophageal junction adenocarcinoma, Esophageal Adenocarcinoma (combination therapy) | Esophageal adenocarcinoma (combination therapy, CAA) | ||
SC, Subsidisation Cap; MES, Managed Entry Scheme; MAA, Managed Access Agreement; CAA, Commercial Access Arrangements All contacts in Korea included provisions for rebates and SC, and contracts in both Australia and the United Kingdom uniformly included provisions for rebates.